Initiates Coverage on Global Cord Blood (NYSE:CO)

Stock analysts at initiated coverage on shares of Global Cord Blood (NYSE:COGet Free Report) in a note issued to investors on Tuesday. The firm set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Price Performance

CO opened at $1.20 on Tuesday. Global Cord Blood has a 52 week low of $2.03 and a 52 week high of $5.50. The business has a fifty day simple moving average of $1.19 and a 200-day simple moving average of $1.34. The firm has a market cap of $145.86 million, a P/E ratio of 1.88 and a beta of 0.16.

About Global Cord Blood

(Get Free Report)

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.

Further Reading

Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with's FREE daily email newsletter.